In March 2025, the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) adopted the updated European Medicines Agencies Network Strategy to 2028 (EMANS 2028). This forward-looking blueprint lays out how the EU’s regulatory network will respond to a rapidly evolving healthcare ecosystem shaped by digital transformation, innovation, public health threats, and shifting global priorities.

For professionals in pharmaceutical medicine, and particularly for learners and alumni of the GMDP Academy, EMANS 2028 offers a critical roadmap. It underscores the need for regulatory agility, interdisciplinary competency, and visionary leadership—qualities that GMDP Academy actively cultivates through its competency-based training programs.

Six Strategic Priorities, One Integrated Vision

The EMANS 2028 strategy is built around six interlinked themes:

  1. Accessibility – Fostering collaboration between regulators, payers, and health technology assessment (HTA) bodies to ensure that medicines are not just authorized, but also accessible to patients across the EU.
  2. Leveraging Data, Digitalisation, and AI – Embracing real-world evidence, health data ecosystems, and artificial intelligence to modernize decision-making and optimize regulatory operations.
  3. Regulatory Science, Innovation, and Competitiveness – Supporting innovation in clinical trials, manufacturing, and stakeholder collaboration to enhance the EU’s global standing as a hub for R&D and therapeutics.
  4. Antimicrobial Resistance (AMR) and Other Health Threats – Building cross-sectoral preparedness, with a One Health approach that integrates human, animal, and environmental health.
  5. Availability and Supply – Tackling medicine shortages through coordinated EU-wide strategies, inspection capacity, and supply chain resilience.
  6. Sustainability of the Network – Investing in regulatory capacity, digital infrastructure, and global partnerships to future-proof the EU medicines system.

Each theme reflects both a challenge and an opportunity—and a clear call to action for professionals engaged in medicines development.

Implications for GMDP Academy Learners

As a premier center for postgraduate education in medicines development, the GMDP Academy’s mission is deeply aligned with EMANS 2028. Through its modular Certification in Medicines Development (CMD) program, delivered in collaboration with King’s College London, the Academy trains professionals in areas such as:

  • Regulatory Affairs, Drug Safety, and Pharmacovigilance
  • Medical Affairs and Health Economics
  • Clinical Trials and Patient Engagement
  • Leadership and Ethics in Global Health

By integrating regulatory trends, digital innovation, and health systems thinking into its curriculum, GMDP Academy ensures that learners are equipped not just to comply with EMANS 2028—but to help lead its implementation across industry, government, and academia.

One Health, One Future

EMANS 2028 also emphasizes the One Health approach—recognizing that the health of people, animals, and the planet are deeply intertwined. This approach is especially relevant for professionals navigating the intersection of regulatory science, public health, and sustainability.

The GMDP Academy reinforces this interdisciplinary thinking across its training modules, ensuring that professionals are prepared to contribute to integrated solutions for antimicrobial resistance, pandemic preparedness, and environmental health.

Conclusion: Preparing for the Future, Today

EMANS 2028 is not merely a strategy document—it’s a statement of intent. It affirms the EU’s commitment to leadership in science, health equity, and global cooperation.

For medicines development professionals, the message is clear: the future of regulation is dynamic, data-driven, and deeply collaborative. Through its internationally recognized training programs, the GMDP Academy stands ready to prepare the next generation of experts who will not only respond to this future—but shape it.

References

European Medicines Agency & Heads of Medicines Agencies. (2025). Seizing opportunities in a changing medicines landscape: The European medicines agencies network strategy to 2028. Luxembourg: Publications Office of the European Union. https://www.ema.europa.eu/en/about-us/how-we-work/european-medicines-regulatory-network/european-medicines-agencies-network-strategyEuropean Medicines Agency. (2025, March 18). European medicines agencies network strategy: Network strategy to 2028. https://www.ema.europa.eu/en/documents/other/seizing-opportunities-changing-medicines-landscape-european-medicines-agencies-network-strategy-2028-final_en.pdf

Disclaimers

  • The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
  • Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
  • No official support by any organization(s) has been provided or should be inferred